Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial

dc.contributor.author	White, M.
dc.contributor.author	Gianni, L.
dc.contributor.author	Lang, I.
dc.contributor.author	Toi, M.
dc.contributor.author	Taran, T.
dc.contributor.author	Jerusalem, G.
dc.contributor.author	Andre, F.
dc.contributor.author	Chen, D.
dc.contributor.author	Robinson, D.
dc.contributor.author	Ozguroglu, M.
dc.date.accessioned	2021-03-04T11:03:57Z
dc.date.available	2021-03-04T11:03:57Z
dc.identifier.citation	Jerusalem G., Andre F., Chen D., Robinson D., Ozguroglu M., Lang I., White M., Toi M., Taran T., Gianni L., "Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial", EUROPEAN JOURNAL OF CANCER, cilt.49, 2013
dc.identifier.issn	0959-8049
dc.identifier.other	vv_1032021
dc.identifier.other	av_706ad0be-5763-4e0a-ab01-74002ab3dfbd
dc.identifier.uri	http://hdl.handle.net/20.500.12627/77480
dc.language.iso	eng
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Klinik Tıp (MED)
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial
dc.type	Makale
dc.relation.journal	EUROPEAN JOURNAL OF CANCER
dc.contributor.department	University of Liege , ,
dc.identifier.volume	49
dc.contributor.firstauthorID	210911

Files in this item

Files	Size	Format	View
There are no files associated with this item.